AzTrials
AzTrials

Functional Neurological Symptom DisorderNCT05086380

Modulation of Sense of Agency With Non-invasive Brain Stimulation and Mindfulness-based Stress Reduction Therapy

A study testing Mindfulness-based stress reduction therapy, Inhibitory TMS and Psychoeducation in people with Functional Neurological Symptom Disorder and Neurological Diseases or Conditions, run by University of Fribourg at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A conversion disorder is a dysfunction of the nervous system in which no structural damage can be demonstrated. However, it must be distinguished from other psychiatric disorders such as psychosis or depression. There are a variety of signs of the disease, such as muscle paralysis, uncontrolled tremors or cramps. Read more about this study

Who is it for?
Ages 17 years and olderHealthy volunteers can take part
What is being tested?
Mindfulness-based stress reduction therapy, Inhibitory TMS and Psychoeducation
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
190 participants
Where
1 siteSwitzerland
Study dates
10 Dec 2021to 16 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Patients:
  • A diagnosis of a functional disorder (such as FND, GTS, PPD, anxiety or depression or others) according to DSM-5 diagnostic and ICD-11 criteria, or
  • A diagnosis of an organic neurological disorder such as stroke, multiple sclerosis (MS), neuromuscular, or movement disorder
  • Aged > 16 years old
  • Willing to participate in the study (by signing the ICF)
  • Capable of judgement
Show all 10Show fewer
  • healthy controls:
  • Aged > 16 years old
  • Willing to participate in the study (by signing the ICF)
  • Capable of judgement

Who cannot join

  • Presence of comorbid psychiatric disorders such as psychosis, current major and severe depression episode, autistic spectrum disorder
  • Past surgery in the brain
  • History of alcohol or drug abuse
  • Botulinum toxin injection in last 3 month
  • Inability to follow the procedure of the study, e.g., due to language problems
  • For organic disorders only: Active severe aphasia, dementia, neglect and acute confusional state, severe pain
Show all 12Show fewer
  • For female participants: breastfeeding, pregnancy or intention to become pregnant (assessed with standard urine test prior to the enrolment in the experiment and before each visit)
  • For MRI and TMS part only: Past surgery in the brain
  • For MRI and TMS part only: Implanted medical devices not-compatible with MRI or TMS (e.g., cochlear implants, infusion pumps, neurostimulators, cardiac pacemakers)
  • For TMS part only: History of actual or suspected epilepsy
  • For TMS part only: Suspected or diagnosed labile or hypertensive blood pressure
  • For Virtual Reality only: No cybersickness

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University of Fribourg

    Fribourg, 1700

Other trials in Switzerland

About this study

Official title: Modulation of the Sense of Agency Across Different Neurological Disorders Using Non-invasive Brain Stimulation and Mindfulness-based Stress Reduction Therapy

A conversion disorder is a dysfunction of the nervous system in which no structural damage can be demonstrated. However, it must be distinguished from other psychiatric disorders such as psychosis or depression. There are a variety of signs of the disease, such as muscle paralysis, uncontrolled tremors or cramps. In rarer cases, blindness, deafness or numbness may occur. Diagnosing this complex disorder has always been a challenge for neurologists and psychiatrists.

This study investigates the effects of transcranial magnetic stimulation (TMS) on the general well-being and symptoms of conversion disorder and other neurological disorders and in comparison to healthy subjects. The TMS method allows to target specific areas of the brain by means of magnetic fields. This technique is not painful and does not have long-lasting effects.

Read more

In addition, the study investigates the effects of mindfulness-based stress reduction on the general well-being and symptoms of conversion disorder and other neurological disorders and compared to healthy subjects. This technique is not painful and has no long-lasting effects.

Furthermore, the study examines movement patterns and symptoms of patients compared to healthy controls while they are in a virtual reality.

Finally, the study examines patients' brain activity while playing a game targeting the sense of agency in real time, which is recorded with an MRI scanner.

The study includes a maximum of twelve sessions in total (ten sessions of approximately 1.5-2 hours each and two sessions each overnight). The planned study methods include TMS, (real-time and normal) magnetic resonance tomography of the brain (MRI "tube"), virtual- and augmented reality (AR/VR), questionnaires, blood, saliva, and motion sensors (e.g., fitness bracelet), and participation in the 8-week mindfulness program.

Being tested
Mindfulness-based stress reduction therapy, Inhibitory TMS, Psychoeducation, TMS sham, Excitatory TMS
Medical subject headings
Conversion Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mindfulness-based stress reduction therapyBehavioural

    MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.

  • Inhibitory TMSDevice

    The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation

  • PsychoeducationBehavioural

    Participants will learn about the symptoms and how to cope with the symptoms

  • TMS shamDevice

    The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex

  • Excitatory TMSDevice

    The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation

  • Virtual RealityDevice

    The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.

  • NeurofeedbackBehavioural

    Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.

Study groups in NCT05086380
Study groupRoleWhat they receive
FND Patients ExperimentalExperimentalGroup of patients with functional neurological disorders
Receives: Behavioral: Mindfulness-based stress reduction therapy; Device: Inhibitory TMS; Device: TMS sham; Device: Excitatory TMS; Device: Virtual Reality; Behavioral: Neurofeedback
Organic controlsActive comparatorGroup of patients with organic neurological disorders
Receives: Device: Inhibitory TMS; Device: TMS sham; Device: Excitatory TMS
Healthy controlsActive comparatorGroup of healthy controls
Receives: Device: Inhibitory TMS; Device: TMS sham; Device: Excitatory TMS; Device: Virtual Reality
FND Patients ComparatorActive comparatorGroup of patients with functional neurological disorders
Receives: Device: Inhibitory TMS; Behavioral: Psychoeducation; Device: TMS sham; Device: Excitatory TMS; Behavioral: Neurofeedback

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in objective Performance Agency Task (TMS)

    The changes in objective performance on the behavioural tasks targeting the sense of agency using the score of an agency task played in the Magnetic Resonance Imaging (MRI) scanner, on a computer or in Virtual Reality before and after brain stimulation (transcranial magnetic stimulation, TMS). The performance is measured by counting the number of targets hit minus the number of obstacles hit during the computer game [-].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 7 to 11 (12 - 16 weeks)

  2. Change in subjective Performance Agency Task (TMS)

    The changes in objective and subjective performance on the behavioural tasks targeting the sense of agency using questionnaires before and after brain stimulation. Participants rate their performance on a visual analog scale (VAS) from 0 to 10 [-].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 7 to 11 (12 - 16 weeks)

  3. Change in objective Performance Agency Task (MBSR)

    The objective performance on the behavioural tasks targeting the sense of agency using the score of an agency task played in the MRI scanner, on a computer or in Virtual Reality before and after a therapeutic intervention (mindfulness-based stress reduction, MBSR).The performance is measured by counting the number of targets hit minus the number of obstacles hit during the computer game [-].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4), visit 7 to 11 (12 - 16 weeks)

  4. Change in subjective Performance Agency Task (MBSR)

    The subjective performance on the behavioural tasks targeting the sense of agency using questionnaires before and after a therapeutic intervention (MBSR). Participants rate their performance on a visual analog scale (VAS) from 0 to 10 [-].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4), visit 7 to 11 (12 - 16 weeks)

Secondary outcomes (35)
  1. task-based fMRI measures TMS

    The functional magnetic resonance imaging (fMRI) measures of blood oxygenation signal (BOLD) in the whole brain during the behavioural task before and after excitatory, inhibitory or sham rTMS, in patients affected by a functional neuropsychiatric disorder (e.g., FND, Gilles de la Tourette Syndrome (GTS), Psychosomatic Pain Disorder (PPD)), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. BOLD is measured in change in intensity between conditions with conditions being before and after rTMS [-].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline)

  2. resting-state fMRI measures TMS

    The fMRI measures of blood oxygenation in the whole brain at rest, before and after excitatory, inhibitory or sham rTMS, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. BOLD is measured in change in functional connectivity between conditions with conditions being before and after rTMS. Functional connectivity is calculated using Pearson's correlation coefficient between pairs of brain regions [-].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline)

  3. DTI measures TMS

    The fMRI measures of blood oxygenation in the whole brain using diffusion tensor imaging (DTI), before and after excitatory, inhibitory or sham rTMS, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. DTI measures the direction and strengths of white matter fibre tracts by measuring the diffusion of water molecules. The measured quantity is the diffusivity or diffusion coefficient, a proportionality constant that relates diffusive flux to a concentration gradient [mm2/s].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline)

  4. task-based fMRI measures MBSR

    The fMRI measures of blood oxygenation in the whole brain during the behavioural task, before and after MBSR or psychoeducation, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). BOLD is measured in change in intensity between conditions with conditions being before and after rTMS [-].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  5. resting-state fMRI measures MBSR

    The fMRI measures of blood oxygenation in the whole brain at rest before and after MBSR or psychoeducation, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). BOLD is measured in change in functional connectivity between conditions with conditions being before and after rTMS. Functional connectivity is calculated using Pearson's correlation coefficient between pairs of brain regions [-].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  6. DTI measures MBSR

    The fMRI measures of blood oxygenation in the whole brain during DTI, before and after MBSR or psychoeducation, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). DTI measures the direction and strengths of white matter fibre tracts by measuring the diffusion of water molecules. The measured quantity is the diffusivity or diffusion coefficient, a proportionality constant that relates diffusive flux to a concentration gradient [mm2/s].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  7. Subjective Agency TMS

    Subjective assessment of own agency during a behavioural task, before and after excitatory, inhibitory or sham rTMS, in patients affected by a functional neuropsychiatric disorder (e.g., FND, Gilles de la Tourette Syndrome (GTS), Psychosomatic Pain Disorder (PPD)), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. Participants rate their performance on a visual analog scale (VAS) from 0 to 10 [-].

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline)

  8. Subjective Agency MBSR

    Subjective assessment of own agency during a behavioural task, before and after MBSR or psychoeducation, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). Participants rate their performance on a visual analog scale (VAS) from 0 to 10 [-].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  9. Neurological Examination TMS

    The performance on an objective neurological examination, before and after excitatory, inhibitory or sham rTMS, in patients affected by a functional neuropsychiatric disorder (e.g., FND, Gilles de la Tourette Syndrome (GTS), Psychosomatic Pain Disorder (PPD)), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). Patients will be examined according to standardized medical examination tests (e.g., positive signs \& A Simplified Version of the Psychogenic Movement Disorders Scale (S-FMDRS) for FND).

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline)

  10. Neurological Examination MBSR

    The performance on an objective neurological examination, before and after MBSR or psychoeducation in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). Patients will be examined according to standardized medical examination tests (e.g., positive signs \& A Simplified Version of the Psychogenic Movement Disorders Scale (S-FMDRS) for FND).

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  11. Objective stress parameters pre/post

    The stress parameters assessed using salivary cortisol before and after MBSR Therapy compared to psychoeducation, in patients affected by a functional neuropsychiatric disorder, an organic condition or in healthy subjects. Cortisol levels are measured using Enzyme-linked Immunosorbent Assay (ELISA) [ng/ul].

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  12. Subjective stress parameters pre/post

    Subjective stress before and after MBSR Therapy compared to psychoeducation, in patients affected by a functional neuropsychiatric disorder, an organic condition or in healthy subjects. Subjective stress is measured using a VAS from 0-100.

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  13. Sleep

    The outcomes of ambient sensors (i.e., actigraphs) monitor non-invasively everyday life activity (ELA), including sleep, in patients affected by a functional neuropsychiatric disorder, an organic condition or in healthy subjects. Actigraphs measure light input and motion. A variety of outcome measures can be calculated such as Time in Bed, Time asleep,

    Measured: Visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4)

  14. Neurofeedback

    The real-time measures of blood oxygenation in the target areas (e.g., TPJ) in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. Participants will receive direct feedback on their performance in the scanner.

    Measured: Visit 7 to 11 (12 - 16 weeks)

  15. Long-term effects on task-based fMRI measures MBSR

    To measure the long-term (six months) effect of MBSR Therapy, the fMRI measures of blood oxygenation signal (BOLD) is measured in the whole brain during the behavioural task, in patients affected by a functional neuropsychiatric disorder (e.g., FND, Gilles de la Tourette Syndrome (GTS), Psychosomatic Pain Disorder (PPD)), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. BOLD is measured in change in intensity between conditions with conditions being at follow-up compared to Visit 5 (after MBSR therapy)[-].

    Measured: At follow-up (6 month after visit 5)

  16. Long-term effects on resting-state fMRI measures MBSR

    To measure the long-term (six months) effect of MBSR Therapy, the fMRI measures of blood oxygenation signal (BOLD) is measured in the whole brain at rest, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. BOLD is measured in change in functional connectivity between conditions with conditions being at follow-up compared to Visit 5 (after MBSR therapy). Functional connectivity is calculated using Pearson's correlation coefficient between pairs of brain regions [-]. .

    Measured: At follow-up (6 month after visit 5)

  17. Long-term effects on DTI measures MBSR

    To measure the long-term (six months) effect of MBSR Therapy, the fMRI measures of blood oxygenation signal (BOLD) is measured in the whole brain during DTI, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke) and healthy subjects. DTI measures the direction and strengths of white matter fibre tracts by measuring the diffusion of water molecules. The measured quantity is the diffusivity or diffusion coefficient, a proportionality constant that relates diffusive flux to a concentration gradient [mm2/s].

    Measured: At follow-up (6 month after visit 5)

  18. Long-term effects on subjective agency MBSR

    To measure the long-term (six months) effect of MBSR therapy, the subjective performance on the behavioural tasks targeting the sense of agency is used. Participants rate their agency on a visual analog scale (VAS) from 0 to 10 [-]. Subjective agency at follow-up will be compared to subjective agency at Visit 5 (after MBSR).

    Measured: At follow-up (6 month after visit 5)

  19. Long-term effects on neurological examination MBSR

    To measure the long-term (six months) effect of MBSR therapy, the performance on an objective neurological examination will be assessed, in patients affected by a functional neuropsychiatric disorder (e.g., FND, GTS, PPD), in comparison to patients affected by an organic condition (e.g., Dystonia, Stroke). Patients will be examined according to standardized medical examination tests (e.g., positive signs \& A Simplified Version of the Psychogenic Movement Disorders Scale (S-FMDRS) for FND). Outcome of neurological assessment at follow-up will be compared to outcome of neurological assessment at Visit 5 (after MBSR).

    Measured: At follow-up (6 month after visit 5)

  20. Long-term effects on objective performance

    To measure the long-term (six months) effect of MBSR therapy, the objective performance on the behavioural tasks targeting the sense of agency is used. The performance is measured by counting the number of targets hit minus the number of obstacles hit during the computer game [-]. Objective performance at follow-up will be compared to objective performance at Visit 5 (after MBSR).

    Measured: At follow-up (6 month after visit 5)

  21. Long-term effects on subjective performance

    To measure the long-term (six months) effect of MBSR therapy, the subjective performance on the behavioural tasks targeting the sense of agency is used. Participants rate their performance on a visual analog scale (VAS) from 0 to 10 [-]. Objective performance at follow-up will be compared to objective performance at Visit 5 (after MBSR).

    Measured: At follow-up (6 month after visit 5)

  22. Neurophysiological measures: MEP

    Motor evoked potential (MEP) is measured by eliciting an action potential using non-invasive brain stimulation (TMS) over the motor cortex through the scalp [% TMS - max. intensity output]. Neurophysiological measures will be used to characterise movement disorders. We will compare MEPs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  23. Neurophysiological measures: MT

    Motor threshold (MT) measures the intensity of a pulse which elicits a predefined MEP. Neurophysiological measures will be used to characterise movement disorders. We will compare MTs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  24. Neurophysiological measures: SICI

    Short IntraCortical Inhibition (SICI) measures the reduction of the MEP occurring after weak (subthreshold) conditioning pulse followed by a supra-threshold test pulse at short interstimulus intervals (approximately 2 msec). Neurophysiological measures will be used to characterise movement disorders. We will compare SICIs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  25. Neurophysiological measures: LICI

    Long IntraCortical Inhibition (LICI) measures the reduction of MEP, as described in Outcome 28, at long interstimulus intervals (between 50 and 200 msec), using supra-threshold paired stimulation. Neurophysiological measures will be used to characterise movement disorders. We will compare LICIs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  26. Neurophysiological measures CSP

    Cortical Silent Period (CSP) measures the period of electromyography (EMG) silence before activity resumes baseline, following the MEP elicited by a pulse to the motor cortex during tonic contraction of a target muscle. Neurophysiological measures will be used to characterise movement disorders. We will compare CSPs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  27. Neurophysiological measures: PAS

    Paired Associative Stimulation (PAS) measures the increase in the MEP amplitude following lowfrequency stimulation over the median nerve of the hand, paired with TMS over the motor cortex. This is an index for plasticity. Neurophysiological measures will be used to characterise movement disorders. We will compare CSPs in patients with a functional, or organic condition, to healthy subjects.

    Measured: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 4 (at least 1 week after visit 3), visit 5 (8 weeks after visit 4) and follow up (6 month after visit 5)

  28. Epigenetic profile

    Mean methylation rates of genes involved in the stress-pathway (i.e., Oxytocin, Serotonine, Dopamine, Glucocorticoid receptor) will be assessed in patients affected by a functional or organic disorder and healthy subjects using blood samples. Methylation profiles will be determined using the bisulfite - treatment method.

    Measured: 1st visit (baseline)

  29. Long-term fluctuations of objective stress parameters

    To assess the long-term (six months) fluctuations of stress, salivary cortisol will be measured at follow-up in patients affected by a functional neuropsychiatric disorder, an organic condition or in healthy subjects. Cortisol levels are measured using Enzyme-linked Immunosorbent Assay (ELISA) [ng/ul].

    Measured: at follow-up (6 month after visit 5)

  30. Long-term fluctuations of subjective stress parameters

    To assess the long-term (six months) fluctuations of stress, subjective stress levels will be measured at follow-up in patients affected by a functional neuropsychiatric disorder, an organic condition or in healthy subjects. Subjective stress is measured using a VAS from 0-100.

    Measured: at follow-up (6 month after visit 5)

  31. Position of focus of attention

    To assess the position of focus of attention we will use eye tracking while participants play a game in virtual reality. We assess where participants focus their attention while moving their limbs

    Measured: at visit 6 (at least one week after visit 5)

  32. Kinematics of limb movements

    To assess the kinematics of movements of participants, we apply motion tracking systems with which we measure movement translation and rotation in space.

    Measured: at visit 6 (at least one week after visit 5)

  33. Stability

    The objective and subjective sway in functional patients, organic control patients and healthy subjects will be assessed using posturography, which includes diverse balance exercises on a force plate (e.g. with eyes open / with eyes closed).

    Measured: Visit 1 (at baseline), and follow up (8 month after visit 1)

  34. Cognition

    Outcomes of neuropsychiatric test battery will be compared in functional patients, organic control patients and healthy subjects (e.g. attention, working memory), and further correlated with the fMRI BOLD signal in e.g., the multimodal vestibular network.

    Measured: Visit 1 (at baseline), and follow up (8 month after visit 1)

  35. Pain processing

    Pain processing and perception of pain will be studied in functional patients, organic patients and healthy subjects by using a standardized tool (i.e. Algopeg). Scores from Algopeg will be associated with neural correlates (e.g., resting state fMRI).

    Measured: Visit 1 (at baseline), and follow up (8 month after visit 1)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2021
  2. Study start10 Dec 2021
  3. Primary completion16 Dec 2024
  4. Study completion16 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
Single blind
Who is masked
Participant
Enrolment
190 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05086380
Sponsor's protocol ID
2020-02283
Status last verified
Feb 2025
First submitted
10 Sep 2021
Last updated
4 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Mindfulness-based stress reduction therapy, Inhibitory TMS and Psychoeducation in people with Functional Neurological Symptom Disorder and Neurological Diseases or Conditions, run by University of Fribourg at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in objective Performance Agency Task (TMS) (time frame: Visit 1 (at baseline), visit 2 (one week after baseline), visit 3 (two weeks after baseline), visit 7 to 11 (12 - 16 weeks)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in